CJC-1295 with DAC – Premium Research Peptide

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analogue designed to extend the half-life of growth hormone–releasing hormone (GHRH) in experimental settings.
This compound is widely used in controlled laboratory environments to study prolonged peptide signalling, endocrine pathway modulation, and receptor-mediated cascades over extended time frames.

This product is supplied strictly as a research-use-only (RUO) reference material and is not intended for human or veterinary use.

For a deeper look at mechanisms and research applications, you can reference the dedicated CJC-1295 with DAC research overview in your peptide blog section.

Product Information

Overview

CJC-1295 with DAC is a long-acting peptide analogue based on growth hormone–releasing hormone (GHRH) fragments that has been modified to incorporate a Drug Affinity Complex.
This modification allows the peptide to bind to circulating plasma proteins, extending its apparent half-life and enabling prolonged receptor engagement in experimental models.

In laboratory settings, CJC-1295 with DAC is used to investigate sustained GHRH receptor activation, downstream endocrine signalling, and long-duration peptide pharmacokinetics.
Because of its extended profile, it is particularly useful in studies focused on comparing short-acting GHRH analogues to long-acting constructs in controlled in vitro and in vivo research models.

Potential Research Applications

• Evaluation of prolonged GHRH receptor activation and signalling dynamics
• Comparative studies of short-acting vs. long-acting peptide analogues
• Endocrine pathway modelling in controlled experimental systems
• Pharmacokinetic and stability profiling of DAC-modified peptides
• Receptor-binding, desensitisation, and downregulation studies
• Combination pathway analysis alongside other signalling peptides in research

Scientific Background

CJC-1295 with DAC was developed to address the rapid clearance and short half-life of native GHRH peptides, which can limit the duration of receptor engagement in standard experimental models.
By covalently attaching a Drug Affinity Complex moiety, CJC-1295 with DAC can interact with serum albumin and other plasma proteins, significantly extending its circulation time.

Preclinical investigations have used CJC-1295 with DAC to characterise:

• Extended activation of GHRH receptors and associated signalling cascades
• Time-dependent changes in downstream anabolic and endocrine markers in experimental systems
• Differences in receptor response profiles between pulsed (short-acting) and sustained (long-acting) exposure
• Structure–activity relationships (SAR) of DAC-conjugated peptide analogues

These studies position CJC-1295 with DAC as a valuable tool compound for researchers examining long-acting peptide pharmacology and receptor signalling dynamics in a controlled laboratory context.

Safety and Handling

CJC-1295 with DAC is supplied for use by qualified professionals in appropriately equipped laboratories only. Standard laboratory personal protective equipment (PPE) such as lab coat, gloves, and eye protection is recommended when handling this material.

• Avoid inhalation, ingestion, or contact with skin and eyes.
• Handle in accordance with institutional safety protocols for research chemicals.
• Dispose of any unused material and waste according to local regulations for peptide-containing laboratory waste.

This material is not intended for human or veterinary administration under any circumstance. No clinical, therapeutic, or dietary use is implied or permitted.

Disclaimer

All information provided is for scientific and educational reference only. CJC-1295 with DAC from Adonis Elite Peptides is supplied strictly as a research-use-only (RUO) laboratory material.

It is not a medicine, drug, or therapeutic product and must not be used for human or veterinary purposes.
End-users are responsible for ensuring compliance with all applicable regulations and guidelines in their jurisdiction before purchase, handling, or experimental use.